Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy (SPECT)

• ClinicalTrials.gov Identifier: NCT03079141
• Recruitment Status: Unknown
• First Posted: March 14, 2017
• Last Update Posted: October 23, 2019
• Sponsor: Leiden University Medical Center
• Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Radboud University Medical Center
• Information provided by (Responsible Party): CJFBoon, Leiden University Medical Center

Study Description

Brief Summary:

Chronic central serous chorioretinopathy (cCSC) is a relatively frequently occurring eye disease that is often diagnosed in patients in the professionally active age range. In this disease, a subretinal fluid accumulation occurs, due to abnormalities in both the choroid and the retinal pigment epithelium. This specific form of macular degeneration can cause permanent vision loss, image distortion, and loss of color and contrast vision. An early diagnosis and treatment may improve the visual outcome and quality of life.

To date there is no international consensus on the optimal treatment of cCSC. Many retrospective studies suggest that treatment with photodynamic therapy (PDT) is effective in chronic CSC. Treatment with oral eplerenone may also be effective in this disease.

In this proposed prospective randomized controlled trial, cCSC patients will be randomized into one of both treatment groups: either half-dose PDT or oral eplerenone treatment. The trial is a superiority study, because retrospective studies suggest that PDT treatment may be more effective than eplerenone treatment.

The null hypothesis of the study is that PDT treatment is more effective than eplerenone treatment in patients with active cCSC. The alternative hypothesis is that PDT treatment is not superior to eplerenone treatment.

Treatment success will not only be based on characteristics on ophthalmological imaging, but also on functional endpoints (both on the outcome of questionnaires, best-corrected visual acuity, and microperimetry), which are most important from a patient's perspective.

The study will take place in 3 large tertiary referral university hospitals in The Netherlands that have extensive experience with conducting clinical trials (Academic Medical Center (Amsterdam, the Netherlands), Radboud University Medical Center (Nijmegen, the Netherlands), and Leiden University Medical Center (Leiden, the Netherlands). Both the Radboud University Medical Center and the Leiden University Medical Center have been involved in the first prospective randomized controlled trial that is currently conducted in cCSC.

This study will last 2 years per participant. Each participant will visit the outpatient clinic for a maximum number of 6 visits.

A total number of 107 patients will be included in the trial. Depending on the speed of inclusion of patients in this trial, the total duration of this study can be determined.

Condition or disease	Intervention/treatment	Phase
Chronic Central Serous Chorioretinopathy	Drug: Eplerenone; Other: Photodynamic therapy	Phase 4

Detailed Description:

Chronic central serous chorioretinopathy (cCSC) is a relatively frequently occurring eye disease that is often diagnosed in patients in the professionally active age range. In this disease, a subretinal fluid accumulation occurs, due to abnormalities in both the choroid and the retinal pigment epithelium. This specific form of macular degeneration can cause permanent vision loss, image distortion, and loss of color and contrast vision. An early diagnosis and treatment may improve the visual outcome and quality of life.

To date there is no international consensus on the optimal treatment of cCSC. Many retrospective studies suggest that treatment with photodynamic therapy (PDT) is effective in chronic CSC. Treatment with oral eplerenone may also be effective in this disease.

In this proposed prospective randomized controlled trial, cCSC patients will be randomized into one of both treatment groups: either half-dose PDT or oral eplerenone treatment. The trial is a superiority study, because retrospective studies suggest that PDT treatment may be more effective than eplerenone treatment.

The null hypothesis of the study is that PDT treatment is more effective than eplerenone treatment in patients with active cCSC. The alternative hypothesis is that PDT treatment is not superior to eplerenone treatment.

Treatment success will not only be based on characteristics on ophthalmological imaging, but also on functional endpoints (both on the outcome of questionnaires, best-corrected visual acuity, and microperimetry), which are most important from a patient's perspective.

The study will take place in 3 large tertiary referral university hospitals in The Netherlands that have extensive experience with conducting clinical trials (Academic Medical Center (Amsterdam, the Netherlands), Radboud University Medical Center (Nijmegen, the Netherlands), and Leiden University Medical Center (Leiden, the Netherlands). Both the Radboud University Medical Center and the Leiden University Medical Center have been involved in the first prospective randomized controlled trial that is currently conducted in cCSC.

This study will last 2 years per participant. Each participant will visit the outpatient clinic for a maximum number of 6 visits, depending on the outcome of treatment. Study evaluations will be mostly part of regular clinical care.

A total number of 107 patients will be included in the trial. Depending on the speed of inclusion of patients in this trial, the total duration of this study can be determined.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 107 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial)
• Actual Study Start Date: February 20, 2017
• Actual Primary Completion Date: August 28, 2019
• Estimated Study Completion Date: August 2021

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Half-dose photodynamic therapy (PDT); In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds. When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment.	Other: Photodynamic therapy; In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds. When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment.
Active Comparator: Oral eplerenone treatment; Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter. When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.	Drug: Eplerenone; Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter. When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment.; Other Name: Inspra

Outcome Measures

Primary Outcome Measures :

1. Absence of subretinal fluid on OCT scan [ Time Frame: 3 months after (start) of treatment ]
   Absence of subretinal fluid on OCT scan

Secondary Outcome Measures :

1. Macular sensitivity on microperimetry [ Time Frame: At evaluation visits during study, depending on the effect of treatment. All patients will visit the outpatient clinic at 3 months, at 1 year, and at 2 years after the (start of) treatment. ]
   Macular sensitivity on microperimetry
2. Mean change in best-corrected visual acuity [ Time Frame: At evaluation visits during study, depending on the effect of treatment. All patients will visit the outpatient clinic at 3 months, at 1 year, and at 2 years after the (start of) treatment. ]
   Mean change in Early Treatment of Diabetic Retinopathy Study best-corrected visual acuity
3. Vision-related quality of life as reported on the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) [ Time Frame: At evaluation visits during study, depending on the effect of treatment. All patients will visit the outpatient clinic at 3 months, at 1 year, and at 2 years after the (start of) treatment. ]
   Vision-related quality of life as reported on the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25)
4. Number of cross-over treatments needed in each treatment arm [ Time Frame: During study. At the evaluation visit at 3 months after the (start of) treatment, a possible cross-over treatment can be performed. ]
   Number of cross-over treatments needed (half-dose photodynamic therapy to eplerenone treatment, and vice versa) in each treatment arm
5. The long-term outcome both after successful treatment and after non-successful treatment [ Time Frame: One year and two year after (start of) therapy ]
   Persistent absence of subretinal fluid on OCT
6. The number of (S)AEs in the 2 different treatment groups. [ Time Frame: At the several evaluation visits within the study, at 3 months, at 1 year, and at 2 years after (the start of) treatment ]
   The number of (S)AEs in the 2 different treatment groups.

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age of ≥ 18 years of age and able to give written informed consent;
• Active chronic central serous chorioretinopathy (cCSC);
• Subjective visual loss > 6 weeks, interpreted as onset of active disease;
• Foveal subretinal fluid (SRF), on optical coherence tomography (OCT), at Baseline Examination;
• ≥1 ill-defined hyperfluorescent leakage areas on fluorescein angiography (FA) with retinal pigment epithelial window defect(s) that are compatible with cCSC;
• Hyperfluorescent areas on indocyanine green angiography (ICGA).

Exclusion Criteria:

• Any previous treatments for active CSC;
• Previous prescription of mineralocorticoid receptor antagonists, for cCSC or for other diseases;
• Current treatment with corticosteroids (topical or systemic), corticosteroid use within 3 months before possible start of trial treatment, or anticipated start of corticosteroid treatment within the first 2 years from the start of the trial period;
• Evidence of another diagnosis that can explain serous SRF or visual loss;
• Best-corrected visual acuity < 20/200 (Snellen equivalent);
• Profound chorioretinal atrophy in central macular area on ophthalmoscopy and OCT;
• Myopia > 6D;
• Visual loss and/or serous detachment on OCT < 6 weeks;
• Continuous and/or progressive visual loss > 18 months or serous detachment on OCT > 18 months;
• No hyperfluorescence on ICGA;
• Intraretinal edema on OCT;
• (relative) Contraindications for FA or ICGA;
• (relative) Contraindications for photodynamic treatment (pregnancy, porphyria, severely disturbed liver function). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening
• (relative) Known contraindications for initiation of eplerenone treatment (hyperkalemia, abnormal renal clearance, severe hepatic insufficiency (Child-Pugh C), type 2 diabetes mellitus with microalbuminuria, concomitant use of potassium supplements, potassium-sparing diuretics, strong CYP3A4 inhibitors, or the combination of an ACE-inhibitor and an angiotensin receptor blocking agent). Pregnancy will not be routinely tested in female patients, but the possibility of pregnancy will be discussed during screening;
• Soft drusen in treated eye or fellow eye, signs of choroidal neovascularization on ophthalmoscopy and/or FA/ICGA of the study eye.

Contacts and Locations

Locations

Netherlands

Academic Medical Center

Amsterdam, Netherlands

Leiden University Medical Center

Leiden, Netherlands

Radboud University Medical Center

Nijmegen, Netherlands

Sponsors and Collaborators

Leiden University Medical Center

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Radboud University Medical Center

Investigators

• Principal Investigator: Camiel JF Boon, MD, PhD; Leiden University Medical Center

More Information

• Responsible Party: CJFBoon, Principal Investigator, Leiden University Medical Center
• ClinicalTrials.gov Identifier: NCT03079141
• Other Study ID Numbers: P16.255
• First Posted: March 14, 2017
• Last Update Posted: October 23, 2019
• Last Verified: October 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: No plan.

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Central Serous Chorioretinopathy; Retinal Diseases; Eye Diseases; Eplerenone; Mineralocorticoid Receptor Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Diuretics, Potassium Sparing; Diuretics; Natriuretic Agents; Antihypertensive Agents